Publications by authors named "Jurij Maurer"

Article Synopsis
  • The LiverRisk score is a proposed blood test aimed at estimating liver stiffness and identifying patients at risk for compensated advanced chronic liver disease (cACLD) and liver-related events without prior known liver issues.
  • In a study involving nearly 7,500 patients, the score's diagnostic performance was evaluated against established methods like FIB-4 and APRI, revealing that while it moderately correlates with liver stiffness measurements, it tends to underestimate them.
  • Although the LiverRisk score demonstrated decent accuracy for predicting cACLD and hepatic decompensation, its limitations include a low negative predictive value, indicating it might not effectively rule out disease in some patients.
View Article and Find Full Text PDF
Article Synopsis
  • The study aimed to create a blood-based algorithm using FIB-4 and VITRO to identify compensated advanced chronic liver disease (cACLD) and clinically significant portal hypertension (CSPH) in patients, especially in settings without access to liver stiffness measurements.
  • A total of 6,143 patients were analyzed; results showed that both LSM and FIB-4 were effective in predicting hepatic decompensation, with a notable risk difference based on FIB-4 levels (≥ 1.75 significantly increasing risk).
  • In a separate cohort, VITRO demonstrated strong diagnostic performance for CSPH, comparable to other established methods, suggesting a reliable means to identify patients at risk for liver-related complications.
View Article and Find Full Text PDF

Background & Aims: Liver stiffness measurements (LSMs) provide an opportunity to monitor liver disease progression and regression noninvasively. We aimed to determine the prognostic relevance of LSM dynamics over time for liver-related events and death in patients with chronic liver disease.

Methods: Patients with chronic liver disease undergoing 2 or more reliable LSMs at least 180 days apart were included in this retrospective cohort study and stratified at baseline (BL) as nonadvanced chronic liver disease (non-ACLD, BL-LSM < 10 kPa), compensated ACLD (cACLD; BL-LSM ≥ 10 kPa), and decompensated ACLD.

View Article and Find Full Text PDF